参考文献/References:
[1] 刘明波,何新叶,杨晓红,等. 《中国心血管健康与疾病报告2023》概要（心血管疾病流行及介入诊疗状况）[J]. 中国介入心脏病学杂志,2024,32(10):541-550.
[2] Tsao CW,Aday AW,Almarzooq ZI,et al. Heart disease and stroke statistics-2023 update:a report from the American Heart Association[J]. Circulation,2023,147(8):e93-e621.
[3] 王治财,仓彦. 代谢组学在冠状动脉粥样硬化性心脏病中的研究进展[J]. 安徽医药,2023,27(7):1293-1297.
[4] Muthubharathi BC,Gowripriya T,Balamurugan K. Metabolomics:small molecules that matter more[J]. Mol Omics,2021,17(2):210-229.
[5] Yang Y,Su C,Zhang XZ,et al. Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2023,1223:123712.
[6] Zhu Q,Qin M,Wang Z,et al. Correction:Plasma metabolomics provides new insights into the relationship between metabolites and outcomes and left ventricular remodeling of coronary artery disease[J]. Cell Bioscience,2022,12(1):201.
[7] Fu H,Zhu K,Zhou D,et al. Identification and validation of plasma metabolomics reveal potential biomarkers for coronary heart disease[J]. Int Heart J,2019,60(6):1387-1397.
[8] Pouralijan Amiri M,Khoshkam M,Salek RM,et al. Metabolomics in early detection and prognosis of acute coronary syndrome[J]. Clin Chim Acta,2019,495:43-53.
[9] Zhao LL,Qiu XJ,Wang WB,et al. NMR metabolomics and random forests models to identify potential plasma biomarkers of blood stasis syndrome with coronary heart disease patients[J]. Front Physiol,2019,10:1109.
[10] Abu-El-Ruz R,Abdel-Rahman ME,Atkin SL,et al. Comparing levels of metabolic predictors of coronary heart disease between healthy lean and overweight females[J]. Metabolites,2021,11(3):169.
[11] Hu J,Yao J,Deng S,et al. Differences in metabolomic profiles between black and white women and risk of coronary heart disease:an observational study of women from four US cohorts[J]. Circ Res,2022,131(7):601-615.
[12] Stein SE,Scott DR. Optimization and testing of mass spectral library search algorithms for compound identification[J]. J Am Soc Mass Spectrom,1994,5(9):859-866.
[13] Maheshwari G,Ringseis R,Wen G,et al. Branched-chain fatty acids as mediators of the activation of hepatic peroxisome proliferator-activated receptor alpha by a fungal lipid extract[J]. Biomolecules,2020,10(9):1259.
[14] Fuior EV,Zvintzou E,Filippatos T,et al. Peroxisome proliferator-activated receptor α in lipoprotein metabolism and atherosclerotic cardiovascular disease[J]. Biomedicines,2023,11(10):2696.
[15] Bidanchi RM,Lalrindika L,Khushboo M,et al. Antioxidative,anti-inflammatory and anti-apoptotic action of ellagic acid against lead acetate induced testicular and hepato-renal oxidative damages and pathophysiological changes in male Long Evans rats[J]. Environ Pollut,2022,302:119048.
[16] Cordeiro JL,Neves JD,Nicola F,et al. Arundic acid (ONO-2506) attenuates neuroinflammation and prevents motor impairment in rats with intracerebral hemorrhage[J]. Cell Mol Neurobiol,2022,42(3):739-751.
[17] Huang F,Pariante CM,Borsini A. From dried bear bile to molecular investigation:A systematic review of the effect of bile acids on cell apoptosis,oxidative stress and inflammation in the brain,across pre-clinical models of neurological,neurodegenerative and neuropsychiatric disorders[J]. Brain Behav Immun,2022,99:132-146.
[18] Van Parys A,Karlsson T,Vinknes KJ,et al. Food sources contributing to intake of choline and individual choline forms in a norwegian cohort of patients with stable angina pectoris[J]. Front Nutr,2021,8:676026.
[19] Huang S,Lim SY,Tan SH,et al. Targeted plasma metabolomics reveals association of acute myocardial infarction risk with the dynamic balance between trimethylamine-n-oxide,betaine,and choline[J]. J Agric Food Chem,2023,71(41):15097-15105.
[20] Actis Dato V,Lange S,Cho Y. Metabolic flexibility of the heart:the role of fatty acid metabolism in health,heart failure,and cardiometabolic diseases[J]. Int J Mol Sci,2024,25(2):1211.
[21] Prado LG,Camara NOS,Barbosa AS. Cell lipid biology in infections:an overview[J]. Front Cell Infect Microbiol,2023,13:1148383.
[22] Steinberg GR,Hardie DG. New insights into activation and function of the AMPK[J]. Nat Rev Mol Cell Biol,2023,24(4):255-272.
[23] Wu B,Chen Y,Clarke R,et al. AMPK signaling regulates mitophagy and mitochondrial atp production in human trophoblast cell line bewo[J]. Front Biosci (Landmark Ed),2022,27(4):118.
[24] Heidary Moghaddam R,Samimi Z,Asgary S,et al. Natural AMPK activators in cardiovascular disease prevention[J]. Front Pharmacol,2021,12:738420.
[25] Dorigatti JD,Thyne KM,Ginsburg BC,et al. Beta-guanidinopropionic acid has age-specific effects on markers of health and function in mice[J]. GeroScience,2021,43(3):1497-1511.
[26] Brewster LM. Paradoxical increase in body mass induced by beta-guanidinopropionic acid in juvenile spontaneously hypertensive rats[J]. Cureus,2021,13(11):e19394.
[27] Crocker CL,Baumgarner BL,Kinsey ST. β-guanidinopropionic acid and metformin differentially impact autophagy, mitochondria and cellular morphology in developing C2C12 muscle cells[J]. J Muscle Res Cell Motil,2020,41(2-3):221-237.
[28] Paavola T,Bergmann U,Kuusisto S,et al. Distinct fatty acid compositions of HDL phospholipids are characteristic of metabolic syndrome and premature coronary heart disease-family study[J]. Int J Mol Sci,2021,22(9):4908.
[29] Li Y,Wang H,Xiao Y,et al. Lipidomics identified novel cholesterol-independent predictors for risk of incident coronary heart disease:Mediation of risk from diabetes and aggravation of risk by ambient air pollution[J]. J Adv Res,2024,65:273-282.
[30] Nitzsche A,Poittevin M,Benarab A,et al. Endothelial S1P1 signaling counteracts infarct expansion in ischemic stroke[J]. Circ Res,2021,128(3):363-382.
[31] Duan Y,Li Q,Wu J,et al. A detrimental role of endothelial S1PR2 in cardiac ischemia-reperfusion injury via modulating mitochondrial dysfunction,NLRP3 inflammasome activation,and pyroptosis [J]. Redox Biol,2024,75:103244.
[32] Ullah E,El-Menyar A,Kunji K,et al. Untargeted metabolomics profiling reveals perturbations in arginine-no metabolism in middle eastern patients with coronary heart disease[J]. Metabolites,2022,12(6):517.
[33] Chen H,Wang Z,Qin M,et al. Comprehensive metabolomics identified the prominent role of glycerophospholipid metabolism in coronary artery disease progression[J]. Front Mol Biosci,2021,8:632950.
[34] Chu C,Liu S,Nie L,et al. The interactions and biological pathways among metabolomics products of patients with coronary heart disease[J]. Biomed Pharmacother,2024,173:116305.
[35] Wang Z,Zhang J,Shi S,et al. Predicting lung adenocarcinoma prognosis,immune escape,and pharmacomic profile from arginine and proline-related genes[J]. Sci Rep,2023,13(1):15198.
[36] Ji X,Chen Z,Wang Q,et al. Sphingolipid metabolism controls mammalian heart regeneration[J]. Cell Metab,2024,36(4):839-856.e8.
[37] Lai Y,Tian Y,You X,et al. Effects of sphingolipid metabolism disorders on endothelial cells[J]. Lipids Health Dis,2022,21(1):101.
[38] Gao X,Guo R,Li Y,et al. Contribution of upregulated aminoacyl-tRNA biosynthesis to metabolic dysregulation in gastric cancer[J]. J Gastroenterol Hepatol,2021,36(11):3113-3126.
[39] Vishweswaraiah S,Yilmaz A,Saiyed N,et al. Integrative analysis unveils the correlation of aminoacyl-trna biosynthesis metabolites with the methylation of the SEPSECS Gene in huntington’s disease brain tissue[J]. Genes (Basel),2023,14(9):1752.
[40] Yang K,Li J,Tao L. Purine metabolism in the development of osteoporosis[J]. Biomed Pharmacother,2022,155:113784.
[41] Liu J,Hong S,Yang J,et al. Targeting purine metabolism in ovarian cancer[J]. J Ovarian Res,2022,15(1):93.
[42] Liu H,Zhang Y,Zhang Q,et al. Metabolism-related prognostic biomarkers, purine metabolism and anti-tumor immunity in colon adenocarcinoma[J]. Front Biosci (Landmark Ed),2023,28(12):328.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(7):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(7):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(7):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(7):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]